nur für Forschungszwecke
Kat.-Nr.S1013
| Verwandte Ziele | HDAC Caspase Secretase MMP HCV Protease Cysteine Protease DPP Tyrosinase HIV Protease Serine Protease |
|---|---|
| Weitere Proteasome Inhibitoren | MG132 Celastrol Epoxomicin (BU-4061T) ONX-0914 (PR-957) Oprozomib Delanzomib VR23 Marizomib (Salinosporamide A) PI-1840 KSQ-4279 (USP1-IN-1) |
| Zelllinien | Assay-Typ | Konzentration | Inkubationszeit | Formulierung | Aktivitätsbeschreibung | PMID |
|---|---|---|---|---|---|---|
| NCI-H1838 | Growth Inhibition Assay | IC50=4186.32 μM | SANGER | |||
| IMR-5 | Growth Inhibition Assay | IC50=3409.62 μM | SANGER | |||
| TE-441-T | Growth Inhibition Assay | IC50=2521.7 μM | SANGER | |||
| U-698-M | Growth Inhibition Assay | IC50=2262.15 μM | SANGER | |||
| COLO-824 | Growth Inhibition Assay | IC50=1261.78 μM | SANGER | |||
| P31-FUJ | Growth Inhibition Assay | IC50=1112.75 μM | SANGER | |||
| KY821 | Growth Inhibition Assay | IC50=1036.04 μM | SANGER | |||
| RPMI-8866 | Growth Inhibition Assay | IC50=1006.28 μM | SANGER | |||
| TC-YIK | Growth Inhibition Assay | IC50=781.01 nM | SANGER | |||
| MS-1 | Growth Inhibition Assay | IC50=759.42 nM | SANGER | |||
| DMS-153 | Growth Inhibition Assay | IC50=746.83 nM | SANGER | |||
| SUP-T1 | Growth Inhibition Assay | IC50=686.04 nM | SANGER | |||
| SCC-15 | Growth Inhibition Assay | IC50=667.47 nM | SANGER | |||
| MSTO-211H | Growth Inhibition Assay | IC50=574.26 nM | SANGER | |||
| J-RT3-T3-5 | Growth Inhibition Assay | IC50=532.57 nM | SANGER | |||
| NCI-H889 | Growth Inhibition Assay | IC50=461.92 nM | SANGER | |||
| CPC-N | Growth Inhibition Assay | IC50=403.77 nM | SANGER | |||
| COLO-668 | Growth Inhibition Assay | IC50=403.57 nM | SANGER | |||
| NCI-H226 | Growth Inhibition Assay | IC50=403.23 nM | SANGER | |||
| TUR | Growth Inhibition Assay | IC50=396.61 nM | SANGER | |||
| DEL | Growth Inhibition Assay | IC50=391.27 nM | SANGER | |||
| NCI-H1963 | Growth Inhibition Assay | IC50=386.19 nM | SANGER | |||
| CA46 | Growth Inhibition Assay | IC50=373.63 nM | SANGER | |||
| SNU-C1 | Growth Inhibition Assay | IC50=362.09 nM | SANGER | |||
| THP-1 | Growth Inhibition Assay | IC50=322.6 nM | SANGER | |||
| SCH | Growth Inhibition Assay | IC50=322.22 nM | SANGER | |||
| NCI-H1522 | Growth Inhibition Assay | IC50=307.05 nM | SANGER | |||
| LNCaP-Clone-FGC | Growth Inhibition Assay | IC50=295.26 nM | SANGER | |||
| NCI-H2171 | Growth Inhibition Assay | IC50=288.92 nM | SANGER | |||
| NCI-H187 | Growth Inhibition Assay | IC50=287.08 nM | SANGER | |||
| KASUMI-1 | Growth Inhibition Assay | IC50=283.05 nM | SANGER | |||
| SK-MEL-2 | Growth Inhibition Assay | IC50=281.9 nM | SANGER | |||
| EW-22 | Growth Inhibition Assay | IC50=263.75 nM | SANGER | |||
| NCI-H1299 | Growth Inhibition Assay | IC50=261.71 nM | SANGER | |||
| COR-L279 | Growth Inhibition Assay | IC50=252.17 nM | SANGER | |||
| NCI-H1155 | Growth Inhibition Assay | IC50=230.32 nM | SANGER | |||
| NCI-H1395 | Growth Inhibition Assay | IC50=210.13 nM | SANGER | |||
| KM-H2 | Growth Inhibition Assay | IC50=197.05 nM | SANGER | |||
| NCI-H209 | Growth Inhibition Assay | IC50=196.52 nM | SANGER | |||
| NCI-H510A | Growth Inhibition Assay | IC50=185.37 nM | SANGER | |||
| NCI-H1304 | Growth Inhibition Assay | IC50=169.21 nM | SANGER | |||
| SCLC-21H | Growth Inhibition Assay | IC50=159.41 nM | SANGER | |||
| NCI-H524 | Growth Inhibition Assay | IC50=159.1 nM | SANGER | |||
| MC116 | Growth Inhibition Assay | IC50=148.85 nM | SANGER | |||
| BV-173 | Growth Inhibition Assay | IC50=122.71 nM | SANGER | |||
| MHH-CALL-2 | Growth Inhibition Assay | IC50=115.7 nM | SANGER | |||
| NCI-H1650 | Growth Inhibition Assay | IC50=115.29 nM | SANGER | |||
| ST486 | Growth Inhibition Assay | IC50=114.06 nM | SANGER | |||
| GR-ST | Growth Inhibition Assay | IC50=113.34 nM | SANGER | |||
| SIG-M5 | Growth Inhibition Assay | IC50=105.06 nM | SANGER | |||
| NCI-H1770 | Growth Inhibition Assay | IC50=102.49 nM | SANGER | |||
| RH-1 | Growth Inhibition Assay | IC50=99.85 nM | SANGER | |||
| AM-38 | Growth Inhibition Assay | IC50=88.08 nM | SANGER | |||
| RL | Growth Inhibition Assay | IC50=86.09 nM | SANGER | |||
| CAL-148 | Growth Inhibition Assay | IC50=81.84 nM | SANGER | |||
| SK-N-FI | Growth Inhibition Assay | IC50=80.2 nM | SANGER | |||
| EW-11 | Growth Inhibition Assay | IC50=78.52 nM | SANGER | |||
| EW-13 | Growth Inhibition Assay | IC50=77.76 nM | SANGER | |||
| ALL-PO | Growth Inhibition Assay | IC50=77.66 nM | SANGER | |||
| KP-N-YS | Growth Inhibition Assay | IC50=76.74 nM | SANGER | |||
| KMS-12-PE | Growth Inhibition Assay | IC50=76.24 nM | SANGER | |||
| NCI-H128 | Growth Inhibition Assay | IC50=74.77 nM | SANGER | |||
| NCI-H322M | Growth Inhibition Assay | IC50=66.11 nM | SANGER | |||
| BT-474 | Growth Inhibition Assay | IC50=65 nM | SANGER | |||
| MRK-nu-1 | Growth Inhibition Assay | IC50=61.82 nM | SANGER | |||
| YT | Growth Inhibition Assay | IC50=61.8 nM | SANGER | |||
| LP-1 | Growth Inhibition Assay | IC50=61.28 nM | SANGER | |||
| P30-OHK | Growth Inhibition Assay | IC50=54.61 nM | SANGER | |||
| NCI-N87 | Growth Inhibition Assay | IC50=54.18 nM | SANGER | |||
| TALL-1 | Growth Inhibition Assay | IC50=53.91 nM | SANGER | |||
| MC-CAR | Growth Inhibition Assay | IC50=51.52 nM | SANGER | |||
| NCI-H720 | Growth Inhibition Assay | IC50=51.11 nM | SANGER | |||
| RS4-11 | Growth Inhibition Assay | IC50=50.88 nM | SANGER | |||
| DMS-79 | Growth Inhibition Assay | IC50=50.71 nM | SANGER | |||
| NCI-H716 | Growth Inhibition Assay | IC50=48.81 nM | SANGER | |||
| RPMI-6666 | Growth Inhibition Assay | IC50=45.89 nM | SANGER | |||
| L-428 | Growth Inhibition Assay | IC50=43.86 nM | SANGER | |||
| SKM-1 | Growth Inhibition Assay | IC50=42.63 nM | SANGER | |||
| NCI-H2227 | Growth Inhibition Assay | IC50=40.49 nM | SANGER | |||
| SHP-77 | Growth Inhibition Assay | IC50=38.03 nM | SANGER | |||
| D-283MED | Growth Inhibition Assay | IC50=37.79 nM | SANGER | |||
| MDA-MB-134-VI | Growth Inhibition Assay | IC50=35.87 nM | SANGER | |||
| C8166 | Growth Inhibition Assay | IC50=35.7 nM | SANGER | |||
| UACC-812 | Growth Inhibition Assay | IC50=35.44 nM | SANGER | |||
| ES3 | Growth Inhibition Assay | IC50=35.19 nM | SANGER | |||
| SK-MEL-1 | Growth Inhibition Assay | IC50=35.17 nM | SANGER | |||
| KARPAS-422 | Growth Inhibition Assay | IC50=35.04 nM | SANGER | |||
| NCI-H719 | Growth Inhibition Assay | IC50=34.31 nM | SANGER | |||
| NCI-H526 | Growth Inhibition Assay | IC50=32.54 nM | SANGER | |||
| EW-3 | Growth Inhibition Assay | IC50=30.59 nM | SANGER | |||
| OCI-AML2 | Growth Inhibition Assay | IC50=29.69 nM | SANGER | |||
| ECC4 | Growth Inhibition Assay | IC50=28.79 nM | SANGER | |||
| WSU-NHL | Growth Inhibition Assay | IC50=28.39 nM | SANGER | |||
| NH-12 | Growth Inhibition Assay | IC50=27.67 nM | SANGER | |||
| LU-165 | Growth Inhibition Assay | IC50=26.72 nM | SANGER | |||
| REH | Growth Inhibition Assay | IC50=26.41 nM | SANGER | |||
| LS-1034 | Growth Inhibition Assay | IC50=25.75 nM | SANGER | |||
| HDLM-2 | Growth Inhibition Assay | IC50=24.54 nM | SANGER | |||
| EC-GI-10 | Growth Inhibition Assay | IC50=24.23 nM | SANGER | |||
| IM-9 | Growth Inhibition Assay | IC50=23.54 nM | SANGER | |||
| DOHH-2 | Growth Inhibition Assay | IC50=23.45 nM | SANGER | |||
| SIMA | Growth Inhibition Assay | IC50=23.38 nM | SANGER | |||
| EW-12 | Growth Inhibition Assay | IC50=23.17 nM | SANGER | |||
| HCC2157 | Growth Inhibition Assay | IC50=23.13 nM | SANGER | |||
| NCI-H82 | Growth Inhibition Assay | IC50=23.02 nM | SANGER | |||
| IST-MES1 | Growth Inhibition Assay | IC50=22.77 nM | SANGER | |||
| NCI-H446 | Growth Inhibition Assay | IC50=21.18 nM | SANGER | |||
| SF539 | Growth Inhibition Assay | IC50=20.67 nM | SANGER | |||
| TE-6 | Growth Inhibition Assay | IC50=20.08 nM | SANGER | |||
| HCC2218 | Growth Inhibition Assay | IC50=19.5 nM | SANGER | |||
| DG-75 | Growth Inhibition Assay | IC50=18.61 nM | SANGER | |||
| NCCIT | Growth Inhibition Assay | IC50=18.36 nM | SANGER | |||
| EoL-1- | Growth Inhibition Assay | IC50=18.31 nM | SANGER | |||
| EB2 | Growth Inhibition Assay | IC50=18.08 nM | SANGER | |||
| NB14 | Growth Inhibition Assay | IC50=17.98 nM | SANGER | |||
| EW-18 | Growth Inhibition Assay | IC50=17.96 nM | SANGER | |||
| MFM-223 | Growth Inhibition Assay | IC50=17.91 nM | SANGER | |||
| COLO-800 | Growth Inhibition Assay | IC50=17.64 nM | SANGER | |||
| GOTO | Growth Inhibition Assay | IC50=17.06 nM | SANGER | |||
| NCI-H1436 | Growth Inhibition Assay | IC50=17.01 nM | SANGER | |||
| U-87-MG | Growth Inhibition Assay | IC50=16.76 nM | SANGER | |||
| TGW | Growth Inhibition Assay | IC50=16.48 nM | SANGER | |||
| JAR | Growth Inhibition Assay | IC50=16.13 nM | SANGER | |||
| NB7 | Growth Inhibition Assay | IC50=15.92 nM | SANGER | |||
| NCI-SNU-1 | Growth Inhibition Assay | IC50=13.19 nM | SANGER | |||
| JVM-3 | Growth Inhibition Assay | IC50=12.99 nM | SANGER | |||
| NCI-H1581 | Growth Inhibition Assay | IC50=12.28 nM | SANGER | |||
| NCI-H23 | Growth Inhibition Assay | IC50=12.12 nM | SANGER | |||
| HCC1599 | Growth Inhibition Assay | IC50=11.91 nM | SANGER | |||
| ES5 | Growth Inhibition Assay | IC50=10.38 nM | SANGER | |||
| NCI-H2081 | Growth Inhibition Assay | IC50=10.09 nM | SANGER | |||
| CTB-1 | Growth Inhibition Assay | IC50=9.67 nM | SANGER | |||
| DMS-114 | Growth Inhibition Assay | IC50=9.62 nM | SANGER | |||
| SK-NEP-1 | Growth Inhibition Assay | IC50=9.01 nM | SANGER | |||
| ATN-1 | Growth Inhibition Assay | IC50=8.89 nM | SANGER | |||
| MLMA | Growth Inhibition Assay | IC50=8.85 nM | SANGER | |||
| NB6 | Growth Inhibition Assay | IC50=8.48 nM | SANGER | |||
| MN-60 | Growth Inhibition Assay | IC50=8.14 nM | SANGER | |||
| KG-1 | Growth Inhibition Assay | IC50=7.94 nM | SANGER | |||
| L-363 | Growth Inhibition Assay | IC50=7.7 nM | SANGER | |||
| NCI-SNU-16 | Growth Inhibition Assay | IC50=7.65 nM | SANGER | |||
| NCI-H1694 | Growth Inhibition Assay | IC50=7.58 nM | SANGER | |||
| LU-134-A | Growth Inhibition Assay | IC50=7.39 nM | SANGER | |||
| JVM-2 | Growth Inhibition Assay | IC50=7.28 nM | SANGER | |||
| SU-DHL-1 | Growth Inhibition Assay | IC50=7.24 nM | SANGER | |||
| NCI-H345 | Growth Inhibition Assay | IC50=7.2 nM | SANGER | |||
| NB1 | Growth Inhibition Assay | IC50=6.88 nM | SANGER | |||
| NCI-H2196 | Growth Inhibition Assay | IC50=6.8 nM | SANGER | |||
| GDM-1 | Growth Inhibition Assay | IC50=6.77 nM | SANGER | |||
| BC-3 | Growth Inhibition Assay | IC50=6.61 nM | SANGER | |||
| D-502MG | Growth Inhibition Assay | IC50=6.37 nM | SANGER | |||
| LU-65 | Growth Inhibition Assay | IC50=5.84 nM | SANGER | |||
| NCI-H1417 | Growth Inhibition Assay | IC50=5.51 nM | SANGER | |||
| EW-1 | Growth Inhibition Assay | IC50=5.31 nM | SANGER | |||
| SW962 | Growth Inhibition Assay | IC50=5.21 nM | SANGER | |||
| NCI-SNU-5 | Growth Inhibition Assay | IC50=5.17 nM | SANGER | |||
| LU-139 | Growth Inhibition Assay | IC50=5.13 nM | SANGER | |||
| CHP-126 | Growth Inhibition Assay | IC50=5.06 nM | SANGER | |||
| SBC-1 | Growth Inhibition Assay | IC50=5.01 nM | SANGER | |||
| JiyoyeP-2003 | Growth Inhibition Assay | IC50=5 nM | SANGER | |||
| MHH-NB-11 | Growth Inhibition Assay | IC50=4.91 nM | SANGER | |||
| MHH-PREB-1 | Growth Inhibition Assay | IC50=4.86 nM | SANGER | |||
| IST-SL1 | Growth Inhibition Assay | IC50=4.68 nM | SANGER | |||
| HL-60 | Growth Inhibition Assay | IC50=4.67 nM | SANGER | |||
| NALM-6 | Growth Inhibition Assay | IC50=4.49 nM | SANGER | |||
| Raji | Growth Inhibition Assay | IC50=4.46 nM | SANGER | |||
| NOMO-1 | Growth Inhibition Assay | IC50=4.33 nM | SANGER | |||
| TE-12 | Growth Inhibition Assay | IC50=4.25 nM | SANGER | |||
| LB647-SCLC | Growth Inhibition Assay | IC50=4.22 nM | SANGER | |||
| OMC-1 | Growth Inhibition Assay | IC50=4.18 nM | SANGER | |||
| NCI-H1648 | Growth Inhibition Assay | IC50=4.13 nM | SANGER | |||
| K-562 | Growth Inhibition Assay | IC50=4.12 nM | SANGER | |||
| NCI-H2141 | Growth Inhibition Assay | IC50=4.05 nM | SANGER | |||
| HD-MY-Z | Growth Inhibition Assay | IC50=3.93 nM | SANGER | |||
| RCC10RGB | Growth Inhibition Assay | IC50=3.93 nM | SANGER | |||
| COLO-320-HSR | Growth Inhibition Assay | IC50=3.92 nM | SANGER | |||
| RL95-2 | Growth Inhibition Assay | IC50=3.79 nM | SANGER | |||
| LC-1F | Growth Inhibition Assay | IC50=3.74 nM | SANGER | |||
| NMC-G1 | Growth Inhibition Assay | IC50=3.68 nM | SANGER | |||
| COLO-684 | Growth Inhibition Assay | IC50=3.66 nM | SANGER | |||
| DJM-1 | Growth Inhibition Assay | IC50=3.63 nM | SANGER | |||
| EVSA-T | Growth Inhibition Assay | IC50=3.6 nM | SANGER | |||
| no-11 | Growth Inhibition Assay | IC50=3.55 nM | SANGER | |||
| MZ1-PC | Growth Inhibition Assay | IC50=3.54 nM | SANGER | |||
| HCC1187 | Growth Inhibition Assay | IC50=3.54 nM | SANGER | |||
| KARPAS-45 | Growth Inhibition Assay | IC50=3.54 nM | SANGER | |||
| RPMI-8402 | Growth Inhibition Assay | IC50=3.5 nM | SANGER | |||
| LOXIMVI | Growth Inhibition Assay | IC50=3.5 nM | SANGER | |||
| MEG-01 | Growth Inhibition Assay | IC50=3.49 nM | SANGER | |||
| LAMA-84 | Growth Inhibition Assay | IC50=3.49 nM | SANGER | |||
| COR-L88 | Growth Inhibition Assay | IC50=3.47 nM | SANGER | |||
| TE-15 | Growth Inhibition Assay | IC50=3.43 nM | SANGER | |||
| DB | Growth Inhibition Assay | IC50=3.41 nM | SANGER | |||
| LB996-RCC | Growth Inhibition Assay | IC50=3.4 nM | SANGER | |||
| NEC8 | Growth Inhibition Assay | IC50=3.35 nM | SANGER | |||
| SK-N-DZ | Growth Inhibition Assay | IC50=3.26 nM | SANGER | |||
| CW-2 | Growth Inhibition Assay | IC50=3.21 nM | SANGER | |||
| SK-PN-DW | Growth Inhibition Assay | IC50=3.14 nM | SANGER | |||
| CGTH-W-1 | Growth Inhibition Assay | IC50=3.1 nM | SANGER | |||
| MONO-MAC-6 | Growth Inhibition Assay | IC50=3.1 nM | SANGER | |||
| KARPAS-299 | Growth Inhibition Assay | IC50=3.06 nM | SANGER | |||
| HT | Growth Inhibition Assay | IC50=3.02 nM | SANGER | |||
| SW954 | Growth Inhibition Assay | IC50=2.9 nM | SANGER | |||
| MOLT-16 | Growth Inhibition Assay | IC50=2.89 nM | SANGER | |||
| C2BBe1 | Growth Inhibition Assay | IC50=2.89 nM | SANGER | |||
| ETK-1 | Growth Inhibition Assay | IC50=2.84 nM | SANGER | |||
| CTV-1 | Growth Inhibition Assay | IC50=2.8 nM | SANGER | |||
| EW-16 | Growth Inhibition Assay | IC50=2.75 nM | SANGER | |||
| Mo-T | Growth Inhibition Assay | IC50=2.74 nM | SANGER | |||
| EB-3 | Growth Inhibition Assay | IC50=2.66 nM | SANGER | |||
| LB1047-RCC | Growth Inhibition Assay | IC50=2.57 nM | SANGER | |||
| KNS-81-FD | Growth Inhibition Assay | IC50=2.48 nM | SANGER | |||
| NB69 | Growth Inhibition Assay | IC50=2.46 nM | SANGER | |||
| NCI-H64 | Growth Inhibition Assay | IC50=2.44 nM | SANGER | |||
| KU812 | Growth Inhibition Assay | IC50=2.42 nM | SANGER | |||
| NCI-H748 | Growth Inhibition Assay | IC50=2.39 nM | SANGER | |||
| ARH-77 | Growth Inhibition Assay | IC50=2.38 nM | SANGER | |||
| SCC-3 | Growth Inhibition Assay | IC50=2.37 nM | SANGER | |||
| RPMI-8226 | Growth Inhibition Assay | IC50=2.35 nM | SANGER | |||
| NB10 | Growth Inhibition Assay | IC50=2.32 nM | SANGER | |||
| BC-1 | Growth Inhibition Assay | IC50=2.31 nM | SANGER | |||
| NB5 | Growth Inhibition Assay | IC50=2.27 nM | SANGER | |||
| KMOE-2 | Growth Inhibition Assay | IC50=2.23 nM | SANGER | |||
| SJSA-1 | Growth Inhibition Assay | IC50=2.21 nM | SANGER | |||
| ES4 | Growth Inhibition Assay | IC50=2.16 nM | SANGER | |||
| KGN | Growth Inhibition Assay | IC50=2.15 nM | SANGER | |||
| EKVX | Growth Inhibition Assay | IC50=2.14 nM | SANGER | |||
| MOLT-4 | Growth Inhibition Assay | IC50=2.13 nM | SANGER | |||
| KE-37 | Growth Inhibition Assay | IC50=2.13 nM | SANGER | |||
| HH | Growth Inhibition Assay | IC50=2.13 nM | SANGER | |||
| GT3TKB | Growth Inhibition Assay | IC50=2.12 nM | SANGER | |||
| BL-70 | Growth Inhibition Assay | IC50=2.12 nM | SANGER | |||
| NOS-1 | Growth Inhibition Assay | IC50=2.11 nM | SANGER | |||
| EW-24 | Growth Inhibition Assay | IC50=2.08 nM | SANGER | |||
| LAN-6 | Growth Inhibition Assay | IC50=2.05 nM | SANGER | |||
| NB17 | Growth Inhibition Assay | IC50=2.04 nM | SANGER | |||
| LS-123 | Growth Inhibition Assay | IC50=2.02 nM | SANGER | |||
| NB13 | Growth Inhibition Assay | IC50=2 nM | SANGER | |||
| NKM-1 | Growth Inhibition Assay | IC50=2 nM | SANGER | |||
| 697 | Growth Inhibition Assay | IC50=1.99 nM | SANGER | |||
| BE-13 | Growth Inhibition Assay | IC50=1.93 nM | SANGER | |||
| MPP-89 | Growth Inhibition Assay | IC50=1.89 nM | SANGER | |||
| Becker | Growth Inhibition Assay | IC50=1.83 nM | SANGER | |||
| MV-4-11 | Growth Inhibition Assay | IC50=1.82 nM | SANGER | |||
| GB-1 | Growth Inhibition Assay | IC50=1.81 nM | SANGER | |||
| NCI-H1092 | Growth Inhibition Assay | IC50=1.8 nM | SANGER | |||
| NCI-H2126 | Growth Inhibition Assay | IC50=1.8 nM | SANGER | |||
| LC4-1 | Growth Inhibition Assay | IC50=1.79 nM | SANGER | |||
| U-266 | Growth Inhibition Assay | IC50=1.76 nM | SANGER | |||
| KURAMOCHI | Growth Inhibition Assay | IC50=1.72 nM | SANGER | |||
| TGBC1TKB | Growth Inhibition Assay | IC50=1.71 nM | SANGER | |||
| EHEB | Growth Inhibition Assay | IC50=1.67 nM | SANGER | |||
| GCIY | Growth Inhibition Assay | IC50=1.62 nM | SANGER | |||
| HEL | Growth Inhibition Assay | IC50=1.61 nM | SANGER | |||
| NB12 | Growth Inhibition Assay | IC50=1.56 nM | SANGER | |||
| NCI-H69 | Growth Inhibition Assay | IC50=1.54 nM | SANGER | |||
| LS-411N | Growth Inhibition Assay | IC50=1.53 nM | SANGER | |||
| PF-382 | Growth Inhibition Assay | IC50=1.47 nM | SANGER | |||
| CAS-1 | Growth Inhibition Assay | IC50=1.37 nM | SANGER | |||
| L-540 | Growth Inhibition Assay | IC50=1.37 nM | SANGER | |||
| ECC12 | Growth Inhibition Assay | IC50=1.37 nM | SANGER | |||
| DU-4475 | Growth Inhibition Assay | IC50=1.36 nM | SANGER | |||
| OPM-2 | Growth Inhibition Assay | IC50=1.33 nM | SANGER | |||
| IST-SL2 | Growth Inhibition Assay | IC50=1.31 nM | SANGER | |||
| Calu-6 | Growth Inhibition Assay | IC50=1.29 nM | SANGER | |||
| CMK | Growth Inhibition Assay | IC50=1.29 nM | SANGER | |||
| A3-KAW | Growth Inhibition Assay | IC50=1.28 nM | SANGER | |||
| K5 | Growth Inhibition Assay | IC50=1.28 nM | SANGER | |||
| KM12 | Growth Inhibition Assay | IC50=1.27 nM | SANGER | |||
| SR | Growth Inhibition Assay | IC50=1.25 nM | SANGER | |||
| BL-41 | Growth Inhibition Assay | IC50=1.25 nM | SANGER | |||
| Daudi | Growth Inhibition Assay | IC50=1.22 nM | SANGER | |||
| NCI-H1882 | Growth Inhibition Assay | IC50=1.2 nM | SANGER | |||
| TE-8 | Growth Inhibition Assay | IC50=1.19 nM | SANGER | |||
| HAL-01 | Growth Inhibition Assay | IC50=1.18 nM | SANGER | |||
| EM-2 | Growth Inhibition Assay | IC50=1.16 nM | SANGER | |||
| CCRF-CEM | Growth Inhibition Assay | IC50=1.13 nM | SANGER | |||
| D-392MG | Growth Inhibition Assay | IC50=1.1 nM | SANGER | |||
| MZ7-mel | Growth Inhibition Assay | IC50=1.09 nM | SANGER | |||
| VA-ES-BJ | Growth Inhibition Assay | IC50=1.09 nM | SANGER | |||
| SK-MM-2 | Growth Inhibition Assay | IC50=1.09 nM | SANGER | |||
| LC-2-ad | Growth Inhibition Assay | IC50=1.08 nM | SANGER | |||
| RKO | Growth Inhibition Assay | IC50=1.06 nM | SANGER | |||
| TE-10 | Growth Inhibition Assay | IC50=1.03 nM | SANGER | |||
| TE-1 | Growth Inhibition Assay | IC50=1.03 nM | SANGER | |||
| PSN1 | Growth Inhibition Assay | IC50=1.01 nM | SANGER | |||
| SW872 | Growth Inhibition Assay | IC50=0.996 nM | SANGER | |||
| HC-1 | Growth Inhibition Assay | IC50=0.975 nM | SANGER | |||
| KALS-1 | Growth Inhibition Assay | IC50=0.925 nM | SANGER | |||
| SF268 | Growth Inhibition Assay | IC50=0.923 nM | SANGER | |||
| IST-MEL1 | Growth Inhibition Assay | IC50=0.917 nM | SANGER | |||
| RXF393 | Growth Inhibition Assay | IC50=0.914 nM | SANGER | |||
| SNB75 | Growth Inhibition Assay | IC50=0.912 nM | SANGER | |||
| NCI-H1355 | Growth Inhibition Assay | IC50=0.895 nM | SANGER | |||
| TE-5 | Growth Inhibition Assay | IC50=0.865 nM | SANGER | |||
| QIMR-WIL | Growth Inhibition Assay | IC50=0.889 nM | SANGER | |||
| SK-LMS-1 | Growth Inhibition Assay | IC50=0.854 nM | SANGER | |||
| SW684 | Growth Inhibition Assay | IC50=0.821 nM | SANGER | |||
| ML-2 | Growth Inhibition Assay | IC50=0.821 nM | SANGER | |||
| D-263MG | Growth Inhibition Assay | IC50=0.807 nM | SANGER | |||
| LB2241-RCC | Growth Inhibition Assay | IC50=0.804 nM | SANGER | |||
| GI-1 | Growth Inhibition Assay | IC50=0.764 nM | SANGER | |||
| ES7 | Growth Inhibition Assay | IC50=0.766 nM | SANGER | |||
| LS-513 | Growth Inhibition Assay | IC50=0.739 nM | SANGER | |||
| KINGS-1 | Growth Inhibition Assay | IC50=0.722 nM | SANGER | |||
| UACC-257 | Growth Inhibition Assay | IC50=0.71 nM | SANGER | |||
| LB373-MEL-D | Growth Inhibition Assay | IC50=0.7 nM | SANGER | |||
| SF126 | Growth Inhibition Assay | IC50=0.701 nM | SANGER | |||
| Ramos-2G6-4C10 | Growth Inhibition Assay | IC50=0.693 nM | SANGER | |||
| TK10 | Growth Inhibition Assay | IC50=0.679 nM | SANGER | |||
| D-336MG | Growth Inhibition Assay | IC50=0.657 nM | SANGER | |||
| BB49-HNC | Growth Inhibition Assay | IC50=0.652 nM | SANGER | |||
| HOP-62 | Growth Inhibition Assay | IC50=0.647 nM | SANGER | |||
| LB831-BLC | Growth Inhibition Assay | IC50=0.641 nM | SANGER | |||
| GI-ME-N | Growth Inhibition Assay | IC50=0.634 nM | SANGER | |||
| A4-Fuk | Growth Inhibition Assay | IC50=0.623 nM | SANGER | |||
| HT-144 | Growth Inhibition Assay | IC50=0.576 nM | SANGER | |||
| COLO-829 | Growth Inhibition Assay | IC50=0.614 nM | SANGER | |||
| NCI-H747 | Growth Inhibition Assay | IC50=0.539 nM | SANGER | |||
| CESS | Growth Inhibition Assay | IC50=0.538 nM | SANGER | |||
| HUTU-80 | Growth Inhibition Assay | IC50=0.533 nM | SANGER | |||
| DSH1 | Growth Inhibition Assay | IC50=0.48 nM | SANGER | |||
| LB771-HNC | Growth Inhibition Assay | IC50=0.474 nM | SANGER | |||
| CP66-MEL | Growth Inhibition Assay | IC50=0.473 nM | SANGER | |||
| OCUB-M | Growth Inhibition Assay | IC50=0.447 nM | SANGER | |||
| MFH-ino | Growth Inhibition Assay | IC50=0.443 nM | SANGER | |||
| OS-RC-2 | Growth Inhibition Assay | IC50=0.44 nM | SANGER | |||
| HCE-T | Growth Inhibition Assay | IC50=0.439 nM | SANGER | |||
| ES1 | Growth Inhibition Assay | IC50=0.43 nM | SANGER | |||
| LB2518-MEL | Growth Inhibition Assay | IC50=0.425 nM | SANGER | |||
| ACN | Growth Inhibition Assay | IC50=0.417 nM | SANGER | |||
| D-247MG | Growth Inhibition Assay | IC50=0.413 nM | SANGER | |||
| HCC2998 | Growth Inhibition Assay | IC50=0.412 nM | SANGER | |||
| MZ2-MEL | Growth Inhibition Assay | IC50=0.407 nM | SANGER | |||
| ES8 | Growth Inhibition Assay | IC50=0.4 nM | SANGER | |||
| A388 | Growth Inhibition Assay | IC50=0.356 nM | SANGER | |||
| KS-1 | Growth Inhibition Assay | IC50=0.34 nM | SANGER | |||
| BB30-HNC | Growth Inhibition Assay | IC50=0.335 nM | SANGER | |||
| ONS-76 | Growth Inhibition Assay | IC50=0.33 nM | SANGER | |||
| D-542MG | Growth Inhibition Assay | IC50=0.329 nM | SANGER | |||
| BB65-RCC | Growth Inhibition Assay | IC50=0.304 nM | SANGER | |||
| LOUCY | Growth Inhibition Assay | IC50=0.293 nM | SANGER | |||
| OVCAR-4 | Growth Inhibition Assay | IC50=0.289 nM | SANGER | |||
| LXF-289 | Growth Inhibition Assay | IC50=0.269 nM | SANGER | |||
| KNS-42 | Growth Inhibition Assay | IC50=0.258 nM | SANGER | |||
| 8-MG-BA | Growth Inhibition Assay | IC50=0.25 nM | SANGER | |||
| NTERA-S-cl-D1 | Growth Inhibition Assay | IC50=0.243 nM | SANGER | |||
| A101D | Growth Inhibition Assay | IC50=0.225 nM | SANGER | |||
| MMAC-SF | Growth Inhibition Assay | IC50=0.216 nM | SANGER | |||
| no-10 | Growth Inhibition Assay | IC50=0.21 nM | SANGER | |||
| A253 | Growth Inhibition Assay | IC50=0.208 nM | SANGER | |||
| TE-9 | Growth Inhibition Assay | IC50=0.182 nM | SANGER | |||
| SH-4 | Growth Inhibition Assay | IC50=0.173 nM | SANGER | |||
| SK-UT-1 | Growth Inhibition Assay | IC50=0.163 nM | SANGER | |||
| ES6 | Growth Inhibition Assay | IC50=0.0021 nM | SANGER | |||
| human PBMC | Function Assay | 100 nM | 24 h | Induces IL-8 release | 25791477 | |
| U937 | Function Assay | 100 nM | 6 h | Induces IL-8 expression in LPS-stimulated U937 macrophages | 25791477 | |
| HH | Migration Assay | 100 nM | 24 h | DMSO | Reduces cell migration by 80–91% | 25681335 |
| Hut-78 | Migration Assay | 100 nM | 24 h | DMSO | Reduces cell migration by 80–90% | 25681335 |
| HH | Function Assay | 100 nM | 24 h | DMSO | downregulates TGF-β1 and IL-12 expression | 25681335 |
| H9 | Function Assay | 100 nM | 24 h | DMSO | Downregulates TGF-β1 and IL-11 expression | 25681335 |
| Hut-78 | Function Assay | 100 nM | 24 h | DMSO | Downregulates TGF-β1 and IL-10 expression | 25681335 |
| H1299 | Apoptosis Assay | 80 nM | 24 h | DMSO | Sensitizes NSCLC cells to MSC-derived iC9-induced apoptosis | 25323693 |
| BLM | Autophagy Assay | 10 nM | 12 h | Induces formation of autophagosomes | 23079083 | |
| A375 | Autophagy Assay | 10 nM | 12 h | Induces formation of autophagosomes | 23079083 | |
| BLM | Apoptosis Assay | 10 nM | 24 h | Induces cell apoptosis | 23079083 | |
| A375 | Apoptosis Assay | 10 nM | 24 h | Induces cell apoptosis | 23079083 | |
| RAW 264.7 | Growth Inhibition Assay | 100 nM | 48 h | Reduces cell viability | 22427154 | |
| SNK-6 | Antiviral Assay | 1 μM | 24 h | Induces lytic infection of EBV | 21170988 | |
| KAI-3 | Antiviral Assay | 1 μM | 24 h | Induces lytic infection of EBV | 21170988 | |
| SNT-16 | Antiviral Assay | 1 μM | 24 h | Induces lytic infection of EBV | 21170988 | |
| SNT-13 | Antiviral Assay | 1 μM | 24 h | Induces lytic infection of EBV | 21170988 | |
| KHYG-1 | Apoptosis Assay | 1 μM | 6 h | Induces cell apoptosis | 21170988 | |
| KAI-3 | Apoptosis Assay | 1 μM | 6 h | Induces cell apoptosis | 21170988 | |
| Jurkat | Apoptosis Assay | 1 μM | 6 h | Induces cell apoptosis | 21170988 | |
| SNT-16 | Apoptosis Assay | 1 μM | 6 h | Induces cell apoptosis | 21170988 | |
| KHYG-1 | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability | 21170988 | |
| SNK-6 | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability | 21170988 | |
| KAI-3 | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability | 21170988 | |
| Jurkat | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability | 21170988 | |
| SNT-16 | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability | 21170988 | |
| SNT-13 | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability | 21170988 | |
| BJAB | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability | 21170988 | |
| LCL-2 | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability | 21170988 | |
| LCL-1 | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability | 21170988 | |
| Raji | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability | 21170988 | |
| BaF/3-p210 | Function Assay | 6 nM | 24 h | Reduces the phosphorylation and the activity of Rb | 20305692 | |
| BaF/3-p210 | Function Assay | 6 nM | 48 h | Induces a slight G1 cell-cycle arrest | 20305692 | |
| BaF/3 | Function Assay | 6 nM | 48 h | Induces a great G1 cell-cycle arrest | 20305692 | |
| TCC-S | Growth Inhibition Assay | 100 nM | 48 h | IC50=2.8 nM | 20305692 | |
| BaF/3-p210 | Growth Inhibition Assay | 100 nM | 48 h | IC50=4.7 nM | 20305692 | |
| BaF/3 | Growth Inhibition Assay | 100 nM | 48 h | IC50=6.2 nM | 20305692 | |
| RPMI 8226 | Function Assay | 20 nM | 8 h | Induces DNA synthesis | 19436050 | |
| OPM2 | Function Assay | 20 nM | 8 h | Significantly enhances NF-κB activity | 19436050 | |
| INA6 | Function Assay | 20 nM | 8 h | Significantly enhances NF-κB activity | 19436050 | |
| OPM1 | Function Assay | 20 nM | 8 h | Significantly enhances NF-κB activity | 19436050 | |
| U266 | Function Assay | 20 nM | 8 h | Significantly enhances NF-κB activity | 19436050 | |
| MM.1S | Function Assay | 20 nM | 8 h | Significantly enhances NF-κB activity | 19436050 | |
| RPMI 8226 | Function Assay | 20 nM | 8 h | Significantly enhances NF-κB activity | 19436050 | |
| CHLA-255 | Function Assay | 10 nM | 24 h | Modestly reduces cells in the G0/G1 phase | 17689684 | |
| NB-1691 | Function Assay | 10 nM | 24 h | Significantly reduces cells in the G0/G1 phase | 17689684 | |
| SK-N-AS | Growth Inhibition Assay | 1 μM | 72 h | Inhibits cell proliferation to 10% | 17689684 | |
| CHLA-255 | Growth Inhibition Assay | 1 μM | 72 h | Inhibits cell proliferation to 2% | 17689684 | |
| NB-1691 | Growth Inhibition Assay | 1 μM | 72 h | Inhibits cell proliferation to 5% | 17689684 | |
| HKe-3 | Apoptosis Assay | 50 nM | 48 h | DMSO | Induces cell apoptosis | 16778179 |
| HCT116 | Apoptosis Assay | 50 nM | 48 h | DMSO | Induces cell apoptosis | 16778179 |
| T29Kt1 | Apoptosis Assay | 50 nM | 48 h | DMSO | Induces cell apoptosis | 16778179 |
| T29 | Apoptosis Assay | 50 nM | 48 h | DMSO | Induces cell apoptosis | 16778179 |
| LNCap-Pro5 | Function Assay | 1 μM | 4 h | DMSO | Stabilizes p53 | 14612532 |
| H460 | Function Assay | 100 nM | 24 h | DMSO | Induces G2-M-phase arrest and tubulin assembly-disassembly | 12631620 |
| H322 | Growth Inhibition Assay | 10 μM | 72 h | DMSO | IC50=620 nM | 12631620 |
| H358 | Growth Inhibition Assay | 10 μM | 72 h | DMSO | IC50=70 nM | 12631620 |
| H460 | Growth Inhibition Assay | 10 μM | 72 h | DMSO | IC50=100 nM | 12631620 |
| RPMI8226/LR5 | Growth Inhibition Assay | 500 ng/ml | 48 h | DMSO | Inhibits cell growth | 12631619 |
| U266/dox4 | Growth Inhibition Assay | 500 ng/ml | 48 h | DMSO | Inhibits cell growth | 12631619 |
| U266/LR7 | Growth Inhibition Assay | 500 ng/ml | 48 h | DMSO | Inhibits cell growth | 12631619 |
| WAD-1 | Growth Inhibition Assay | 500 ng/ml | 48 h | DMSO | Inhibits cell growth | 12631619 |
| ARH77 | Growth Inhibition Assay | 500 ng/ml | 48 h | DMSO | Inhibits cell growth | 12631619 |
| U266 | Growth Inhibition Assay | 500 ng/ml | 48 h | DMSO | Inhibits cell growth | 12631619 |
| H460 | Function Assay | 10 μM | 24 h | DMSO | Induces Bcl-2 phosphorylation and cleavage correlated with G2-M phase arrest | 12492117 |
| UM-SCC-11B | Growth Inhibition Assay | 100 nM | 72 h | DMSO | Inhibits cell viability | 11350913 |
| UM-SCC-9 | Growth Inhibition Assay | 100 nM | 72 h | DMSO | Inhibits cell viability | 11350913 |
| B7E3 | Growth Inhibition Assay | 100 nM | 72 h | DMSO | Inhibits cell viability | 11350913 |
| B4B8 | Growth Inhibition Assay | 100 nM | 72 h | DMSO | Inhibits cell viability | 11350913 |
| PAM-LY2 | Growth Inhibition Assay | 100 nM | 72 h | DMSO | Inhibits cell viability | 11350913 |
| PAM 212 | Growth Inhibition Assay | 100 nM | 72 h | DMSO | Inhibits cell viability | 11350913 |
| PAM-LY2 | Function Assay | 100 nM | 12 h | DMSO | Inhibits NF-κB activation | 11350913 |
| Hs Sultan | Growth Inhibition Assay | 100 nM | 48 h | DMSO | IC50=20 nM | 11306489 |
| IM-9 | Growth Inhibition Assay | 100 nM | 48 h | DMSO | IC50=6 nM | 11306489 |
| U266 | Growth Inhibition Assay | 100 nM | 48 h | DMSO | IC50=3 nM | 11306489 |
| LR5 | Growth Inhibition Assay | 100 nM | 48 h | DMSO | IC50=20 nM | 11306489 |
| MR20 | Growth Inhibition Assay | 100 nM | 48 h | DMSO | IC50=20 nM | 11306489 |
| Dox40 | Growth Inhibition Assay | 100 nM | 48 h | DMSO | IC50=40 nM | 11306489 |
| RPMI8226 | Growth Inhibition Assay | 100 nM | 48 h | DMSO | IC50=30 nM | 11306489 |
| OVCA 429 | Function Assay | 300 nM | 48 h | DMSO | Disrupts intact multicellular tumor spheroids | 10999766 |
| MCF-7 | Cytotoxic Assay | 50 μM | 48 h | DMSO | Kills cells by more than 99% | 10499643 |
| FSCLL | Cytotoxicity assay | 24 hrs | CC50 = 0.004 μM | 21634429 | ||
| HEK293 | Cytotoxicity assay | 24 hrs | CC50 = 0.347 μM | 21634429 | ||
| Glioma (HF2303) | Cytotoxicity assay | 72 hrs | EC50 = 0.0007 μM | 26288699 | ||
| Glioma (HF2476) | Cytotoxicity assay | 72 hrs | EC50 = 0.0007 μM | 26288699 | ||
| Glioma (HF2876) | Cytotoxicity assay | 72 hrs | EC50 = 0.0007 μM | 26288699 | ||
| Glioma (HF2885) | Cytotoxicity assay | 72 hrs | EC50 = 0.0007 μM | 26288699 | ||
| Glioma (HF3013) | Cytotoxicity assay | 72 hrs | EC50 = 0.0007 μM | 26288699 | ||
| Glioma (HF2381) | Cytotoxicity assay | 72 hrs | EC50 = 0.0007 μM | 26288699 | ||
| Glioma (HF2790) | Cytotoxicity assay | 72 hrs | EC50 = 0.0007 μM | 26288699 | ||
| HepG2 | Cytotoxicity assay | 48 hrs | EC50 = 0.01 μM | 29800827 | ||
| Molt4 | Function assay | EC50 = 0.021 μM | 18247547 | |||
| Molt4 | Function assay | EC50 = 0.021 μM | 22503349 | |||
| HL60 | Function assay | 10 mins | ED50 = 0.0025 μM | 19422206 | ||
| HL60 | Function assay | 10 mins | ED50 = 0.0025 μM | 21973101 | ||
| RPMI8226 | Growth inhibition assay | GI50 = 0.00023 μM | 24946214 | |||
| CCRF-CEM | Growth inhibition assay | GI50 = 0.00035 μM | 24946214 | |||
| MDA-MB-435 | Growth inhibition assay | GI50 = 0.00044 μM | 24946214 | |||
| MALME-3M | Growth inhibition assay | GI50 = 0.00045 μM | 24946214 | |||
| NCI-H226 | Growth inhibition assay | GI50 = 0.00046 μM | 24946214 | |||
| SK-MEL-28 | Growth inhibition assay | GI50 = 0.00046 μM | 24946214 | |||
| A498 | Growth inhibition assay | GI50 = 0.00048 μM | 24946214 | |||
| MOLT4 | Growth inhibition assay | GI50 = 0.00051 μM | 24946214 | |||
| OVCAR3 | Growth inhibition assay | GI50 = 0.00054 μM | 24946214 | |||
| SW620 | Growth inhibition assay | GI50 = 0.00055 μM | 24946214 | |||
| MCF7 | Growth inhibition assay | GI50 = 0.00055 μM | 24946214 | |||
| BT549 | Growth inhibition assay | GI50 = 0.00055 μM | 24946214 | |||
| UACC257 | Growth inhibition assay | GI50 = 0.00059 μM | 24946214 | |||
| SF539 | Growth inhibition assay | GI50 = 0.00059 μM | 24946214 | |||
| HCC2998 | Growth inhibition assay | GI50 = 0.0006 μM | 24946214 | |||
| HCT116 | Growth inhibition assay | GI50 = 0.0006 μM | 24946214 | |||
| T47D | Growth inhibition assay | GI50 = 0.0006 μM | 24946214 | |||
| CAKI-1 | Growth inhibition assay | GI50 = 0.00066 μM | 24946214 | |||
| SK-MEL-5 | Growth inhibition assay | GI50 = 0.00068 μM | 24946214 | |||
| RXF393 | Growth inhibition assay | GI50 = 0.00071 μM | 24946214 | |||
| LOXIMVI | Growth inhibition assay | GI50 = 0.00078 μM | 24946214 | |||
| ACHN | Growth inhibition assay | GI50 = 0.00079 μM | 24946214 | |||
| SR | Growth inhibition assay | GI50 = 0.00085 μM | 24946214 | |||
| UACC62 | Growth inhibition assay | GI50 = 0.00091 μM | 24946214 | |||
| M14 | Growth inhibition assay | GI50 = 0.00093 μM | 24946214 | |||
| HT-29 | Growth inhibition assay | GI50 = 0.00095 μM | 24946214 | |||
| HOP92 | Growth inhibition assay | GI50 = 0.001 μM | 24946214 | |||
| NCI-H23 | Growth inhibition assay | GI50 = 0.001 μM | 24946214 | |||
| TK10 | Growth inhibition assay | GI50 = 0.001 μM | 24946214 | |||
| CEM | Antiproliferative assay | 72 hrs | GI50 = 0.001 μM | 28441582 | ||
| U266 | Antiproliferative assay | 72 hrs | GI50 = 0.001 μM | 28441582 | ||
| Hs 578T | Growth inhibition assay | GI50 = 0.00102 μM | 24946214 | |||
| UO31 | Growth inhibition assay | GI50 = 0.00105 μM | 24946214 | |||
| SK-MEL-2 | Growth inhibition assay | GI50 = 0.00107 μM | 24946214 | |||
| SN12C | Growth inhibition assay | GI50 = 0.0011 μM | 24946214 | |||
| K562 | Growth inhibition assay | GI50 = 0.00117 μM | 24946214 | |||
| SF268 | Growth inhibition assay | GI50 = 0.00117 μM | 24946214 | |||
| COLO205 | Growth inhibition assay | GI50 = 0.00123 μM | 24946214 | |||
| MDA-MB-231 | Growth inhibition assay | GI50 = 0.00126 μM | 24946214 | |||
| NCI-H522 | Growth inhibition assay | GI50 = 0.00144 μM | 24946214 | |||
| 786-0 | Growth inhibition assay | GI50 = 0.00144 μM | 24946214 | |||
| MDA-MB-468 | Growth inhibition assay | GI50 = 0.00148 μM | 24946214 | |||
| HCT15 | Growth inhibition assay | GI50 = 0.00151 μM | 24946214 | |||
| U251 | Growth inhibition assay | GI50 = 0.00155 μM | 24946214 | |||
| OVCAR5 | Growth inhibition assay | GI50 = 0.00155 μM | 24946214 | |||
| KM12 | Growth inhibition assay | GI50 = 0.0017 μM | 24946214 | |||
| SF295 | Growth inhibition assay | GI50 = 0.0017 μM | 24946214 | |||
| DU145 | Growth inhibition assay | GI50 = 0.0017 μM | 24946214 | |||
| HL-60(TB) | Growth inhibition assay | GI50 = 0.0019 μM | 24946214 | |||
| OVCAR4 | Growth inhibition assay | GI50 = 0.00195 μM | 24946214 | |||
| SNB19 | Growth inhibition assay | GI50 = 0.00204 μM | 24946214 | |||
| SNB75 | Growth inhibition assay | GI50 = 0.00204 μM | 24946214 | |||
| IGROV1 | Growth inhibition assay | GI50 = 0.00224 μM | 24946214 | |||
| OVCAR8 | Growth inhibition assay | GI50 = 0.00263 μM | 24946214 | |||
| PC3 | Growth inhibition assay | GI50 = 0.00263 μM | 24946214 | |||
| EKVX | Growth inhibition assay | GI50 = 0.00302 μM | 24946214 | |||
| A549/ATCC | Growth inhibition assay | GI50 = 0.00309 μM | 24946214 | |||
| HOP62 | Growth inhibition assay | GI50 = 0.00447 μM | 24946214 | |||
| NCI-H460 | Growth inhibition assay | GI50 = 0.00447 μM | 24946214 | |||
| K562 | Antiproliferative assay | 72 hrs | GI50 = 0.007 μM | 28441582 | ||
| NCI-ADR-RES | Growth inhibition assay | GI50 = 0.0123 μM | 24946214 | |||
| SKOV3 | Growth inhibition assay | GI50 = 0.0138 μM | 24946214 | |||
| NCI-H322M | Growth inhibition assay | GI50 = 0.0178 μM | 24946214 | |||
| DLD1 | Function assay | 6 hrs | IC50 = 0.0002 μM | 22206869 | ||
| DLD1 | Function assay | 6 hrs | IC50 = 0.0009 μM | 22206869 | ||
| HCT116 | Cytotoxicity assay | 72 hrs | IC50 = 0.001 μM | 28634039 | ||
| HCT116 | Antiproliferative assay | 72 hrs | IC50 = 0.0014 μM | 27769033 | ||
| HepG2 | Antiproliferative assay | 72 hrs | IC50 = 0.00161 μM | 27769033 | ||
| SKOV3 | Antiproliferative assay | 72 hrs | IC50 = 0.00162 μM | 27769033 | ||
| A2780 | Cytotoxicity assay | IC50 = 0.0017 μM | 18247547 | |||
| DOGUM | Cytotoxicity assay | 72 hrs | IC50 = 0.002 μM | 23031590 | ||
| U266 | Cytotoxicity assay | 72 hrs | IC50 = 0.00245 μM | 19537716 | ||
| A549 | Antiproliferative assay | 72 hrs | IC50 = 0.0025 μM | 28182990 | ||
| HL60 | Antiproliferative assay | 72 hrs | IC50 = 0.0032 μM | 28182990 | ||
| RPMI18226 | Cytotoxicity assay | 72 hrs | IC50 = 0.0035 μM | 21077681 | ||
| HL60 | Cytotoxicity assay | 72 hrs | IC50 = 0.0035 μM | 21077681 | ||
| RPMI8226 | Cytotoxicity assay | 72 hrs | IC50 = 0.00388 μM | 26965867 | ||
| HL60 | Function assay | 2 hrs | IC50 = 0.004 μM | 27769033 | ||
| U266 | Function assay | 1 hr | IC50 = 0.004 μM | 28441582 | ||
| HL60 | Function assay | 2 hrs | IC50 = 0.004 μM | 28634039 | ||
| SEM | Function assay | 2 hrs | IC50 = 0.00443 μM | 30365892 | ||
| HL60 | Cytotoxicity assay | 72 hrs | IC50 = 0.0055 μM | 19537716 | ||
| U266 | Cytotoxicity assay | 72 hrs | IC50 = 0.00573 μM | 26965867 | ||
| MGC803 | Antiproliferative assay | 72 hrs | IC50 = 0.005782 μM | 27769033 | ||
| GUMBUS | Cytotoxicity assay | 72 hrs | IC50 = 0.006 μM | 23031590 | ||
| ARH77 | Cytotoxicity assay | 72 hrs | IC50 = 0.00607 μM | 26965867 | ||
| SW480 | Cytotoxicity assay | 72 hrs | IC50 = 0.0061 μM | 20158184 | ||
| MDA-MB-231 | Antiproliferative assay | 72 hrs | IC50 = 0.0065 μM | 28182990 | ||
| HL60 | Function assay | 2 hrs | IC50 = 0.00667 μM | 30365892 | ||
| A549 | Cytotoxicity assay | 72 hrs | IC50 = 0.0067 μM | 20158184 | ||
| RPMI8226 | Antiproliferative assay | 72 hrs | IC50 = 0.0067 μM | 28182990 | ||
| 5TGM1 | Cytotoxicity assay | 48 to 72 hrs | IC50 = 0.00678 μM | 24119559 | ||
| HL60 | Cytotoxicity assay | 72 hrs | IC50 = 0.0069 μM | 19747832 | ||
| PC3 | Cytotoxicity assay | 72 hrs | IC50 = 0.007 μM | 20158184 | ||
| DOGUM | Cytotoxicity assay | 72 hrs | IC50 = 0.007 μM | 23031590 | ||
| HL60 | Cytotoxicity assay | 72 hrs | IC50 = 0.0071 μM | 20158184 | ||
| MKN45 | Antiproliferative assay | 72 hrs | IC50 = 0.00715 μM | 27769033 | ||
| HepG2 | Cytotoxicity assay | 72 hrs | IC50 = 0.0075 μM | 20158184 | ||
| HL60 | Antiproliferative assay | 72 hrs | IC50 = 0.0076 μM | 27769033 | ||
| RPMI8226 | Cytotoxic activity against human | 72 hrs | IC50 = 0.00796 μM | 24767818 | ||
| HL60 | Cytotoxicity assay | 72 hrs | IC50 = 0.008 μM | 28634039 | ||
| MGC803 | Cytotoxicity assay | 72 hrs | IC50 = 0.008 μM | 28634039 | ||
| SKOV3/TR | Function assay | 4 days | IC50 = 0.008 μM | 29767973 | ||
| PC3 | Cytotoxicity assay | 72 hrs | IC50 = 0.0083 μM | 21077681 | ||
| U266 | Cytotoxicity assay | 72 hrs | IC50 = 0.0088 μM | 20158184 | ||
| RPMI8226 | Cytotoxicity assay | IC50 = 0.0088 μM | 20727746 | |||
| RPMI8226 | Cytotoxicity assay | 48 to 72 hrs | IC50 = 0.0095 μM | 24119559 | ||
| ARH77 | Cytotoxicity assay | 72 hrs | IC50 = 0.00957 μM | 29934218 | ||
| HEK293 | Function assay | 3 hrs | IC50 = 0.01 μM | 20875739 | ||
| HCT116 | Cytotoxicity assay | 72 hrs | IC50 = 0.01 μM | 23547757 | ||
| NCI-H929 | Cytotoxicity assay | 72 hrs | IC50 = 0.01085 μM | 24767818 | ||
| CCRF-CEM | Antiproliferative assay | 72 hrs | IC50 = 0.011 μM | 26231162 | ||
| RPMI8226 | Cytotoxicity assay | 72 hrs | IC50 = 0.0112 μM | 29934218 | ||
| U266B1 | Cytotoxicity assay | 72 hrs | IC50 = 0.01163 μM | 29934218 | ||
| BxPC3 | Cytotoxicity assay | 72 hrs | IC50 = 0.0118 μM | 19747832 | ||
| 293T | Antiproliferative assay | 72 hrs | IC50 = 0.012 μM | 28191850 | ||
| U266 | Cytotoxicity assay | 72 hrs | IC50 = 0.0122 μM | 19747832 | ||
| SW480 | Cytotoxicity assay | 72 hrs | IC50 = 0.0123 μM | 21077681 | ||
| SKOV3 | Cytotoxicity assay | 4 days | IC50 = 0.0129 μM | 29767973 | ||
| A549 | Cytotoxicity assay | 72 hrs | IC50 = 0.0139 μM | 21077681 | ||
| HEK293 | Function assay | 30 mins | IC50 = 0.014 μM | 21044847 | ||
| RPMI8266 | Antiproliferative assay | 72 hrs | IC50 = 0.0144 μM | 26231162 | ||
| BxPC3 | Cytotoxicity assay | 72 hrs | IC50 = 0.0162 μM | 20158184 | ||
| MDA-MB-231 | Antiproliferative assay | 72 hrs | IC50 = 0.01665 μM | 27769033 | ||
| TOV21G | Antiproliferative assay | 72 hrs | IC50 = 0.0167 μM | 26231162 | ||
| MDA-MB-231 | Cytotoxicity assay | 72 hrs | IC50 = 0.017 μM | 28634039 | ||
| BxPC3 | Cytotoxicity assay | 72 hrs | IC50 = 0.0194 μM | 21077681 | ||
| HeLa | Growth inhibition assay | 72 hrs | IC50 = 0.02 μM | 19428245 | ||
| RKO | Antiproliferative assay | 72 hrs | IC50 = 0.0208 μM | 26231162 | ||
| MCF7 | Antiproliferative assay | 3 days | IC50 = 0.025 μM | 28557430 | ||
| Bel7404 | Antiproliferative assay | 72 hrs | IC50 = 0.02504 μM | 27769033 | ||
| HepG2 | Cytotoxicity assay | 72 hrs | IC50 = 0.0252 μM | 21077681 | ||
| HEK293 | Function assay | 24 hrs | IC50 = 0.027 μM | 21634429 | ||
| HCT116 | Antiproliferative assay | 72 hrs | IC50 = 0.027 μM | 26231162 | ||
| SUP-B15 | Function assay | 2 hrs | IC50 = 0.02809 μM | 30365892 | ||
| A431 | Antiproliferative assay | 72 hrs | IC50 = 0.0282 μM | 26231162 | ||
| A2780 | Antiproliferative assay | 72 hrs | IC50 = 0.0289 μM | 28182990 | ||
| HL60 | Function assay | 2 hrs | IC50 = 0.03 μM | 27769033 | ||
| HL60 | Function assay | 2 hrs | IC50 = 0.03 μM | 28634039 | ||
| HEK293 | Function assay | 6 hrs | IC50 = 0.03 μM | 28919340 | ||
| WM266.4 | Cytotoxicity assay | 72 hrs | IC50 = 0.035 μM | 22206869 | ||
| GUMBUS | Cytotoxicity assay | 72 hrs | IC50 = 0.035 μM | 23031590 | ||
| HepG2 | Cytotoxicity assay | 72 hrs | IC50 = 0.0375 μM | 19537716 | ||
| 95-D | Cytotoxicity assay | 72 hrs | IC50 = 0.038 μM | 28634039 | ||
| 95-D | Antiproliferative assay | 72 hrs | IC50 = 0.03818 μM | 27769033 | ||
| SW480 | Cytotoxicity assay | 72 hrs | IC50 = 0.05 μM | 19537716 | ||
| KB | Cytotoxicity assay | 72 hrs | IC50 = 0.0595 μM | 19537716 | ||
| SKOV3 | Cytotoxicity assay | 72 hrs | IC50 = 0.0668 μM | 21077681 | ||
| SW1990 | Antiproliferative assay | 72 hrs | IC50 = 0.07906 μM | 27769033 | ||
| HeLa | Cytotoxicity assay | 72 hrs | IC50 = 0.092 μM | 19537716 | ||
| A549 | Antiproliferative assay | 72 hrs | IC50 = 0.092 μM | 28191850 | ||
| H460 | Cytotoxicity assay | 72 hrs | IC50 = 0.115 μM | 19537716 | ||
| SKOV3 | Cytotoxicity assay | 72 hrs | IC50 = 0.13 μM | 19537716 | ||
| SKOV3 | Cytotoxicity assay | 72 hrs | IC50 = 0.151 μM | 20158184 | ||
| A549 | Cytotoxicity assay | 72 hrs | IC50 = 0.255 μM | 19537716 | ||
| HL60 | Function assay | 2 hrs | IC50 = 0.44 μM | 27769033 | ||
| HL60 | Function assay | 2 hrs | IC50 = 0.44 μM | 28634039 | ||
| H460 | Cytotoxicity assay | 72 hrs | IC50 = 0.78 μM | 20158184 | ||
| BGC823 | Cytotoxicity assay | 72 hrs | IC50 = 0.88 μM | 19537716 | ||
| MCF7 | Antiproliferative assay | 72 hrs | IC50 = 18.37 μM | 29426629 | ||
| A549 | Antiproliferative assay | 72 hrs | IC50 = 2.13573 μM | 27769033 | ||
| A549 | Cytotoxicity assay | 72 hrs | IC50 = 2.14 μM | 28634039 | ||
| BGC823 | Cytotoxicity assay | 72 hrs | IC50 = 2.89 μM | 19747832 | ||
| MDA-MB-231 | Antiproliferative assay | 72 hrs | IC50 = 3.125 μM | 29426629 | ||
| BCG823 | Cytotoxicity assay | 72 hrs | IC50 = 3.29 μM | 20158184 | ||
| A549 | Antiproliferative assay | 72 hrs | IC50 = 9.318 μM | 29426629 | ||
| Calu6 | Cytotoxicity assay | 72 hrs | LC50 = 0.0061 μM | 20875739 | ||
| HEK293T | Antiproliferative assay | 48 hrs | LC50 = 0.016 μM | 29843100 | ||
| LO2 | Antiproliferative assay | 48 hrs | LC50 = 0.398 μM | 29843100 | ||
| NCI-H929 | Cytotoxicity assay | 48 hrs | LD50 = 0.0066 μM | 27994734 | ||
| U266 | Cytotoxicity assay | 48 hrs | LD50 = 0.018 μM | 27994734 | ||
| LCL | Cytotoxicity assay | 48 hrs | LD50 = 0.02 μM | 27994734 | ||
| MDA-MB-468 | Cytotoxicity assay | 48 hrs | LD50 = 0.037 μM | 27994734 | ||
| RD-ES | Cytotoxicity assay | 48 hrs | LD50 = 0.04 μM | 27994734 | ||
| WE68 | Cytotoxicity assay | 48 hrs | LD50 = 0.1 μM | 27994734 | ||
| IMR90 | Cytotoxicity assay | 48 hrs | LD50 = 0.13 μM | 27994734 | ||
| KGN | Cytotoxicity assay | 48 hrs | LD50 = 0.18 μM | 27994734 | ||
| HNDF | Cytotoxicity assay | 48 hrs | LD50 = 0.48 μM | 27994734 | ||
| MCF10A | Cytotoxicity assay | 48 hrs | LD50 = 1.5 μM | 27994734 | ||
| SKOV3 | Cytotoxicity assay | 48 hrs | LD50 = 1.6 μM | 27994734 | ||
| MCF7 | Cytotoxicity assay | 48 hrs | LD50 = 9.8 μM | 27994734 | ||
| HL60 | Function assay | 100 nM | Inhibition of chymotrypsin-like activity of proteasome in human HL60 cells at 100 nM | 19655762 | ||
| HeLa | Function assay | 5 nM | 8 hrs | Inhibition of proteasome activity in human HeLa cells assessed as induction of ubiquitinG76V-FL reporter level at 5 nM after 8 hrs by luciferase assay | 21186794 | |
| HeLa | Function assay | 1 uM | 8 hrs | Inhibition of proteasome activity in human HeLa cells assessed as induction of ubiquitinG76V-FL reporter level at 1 uM after 8 hrs by luciferase assay | 21186794 | |
| LN229 | Function assay | 100 nM | 1 hr | Inhibition of HIF1alpha expression in human LN229 cells assessed as reduction of HIF-1alpha accumulation at 100 nM preincubated for 1 hr under normoxia condition followed by 24 hrs incubation under hypoxia condition by Western blotting | 21831638 | |
| LN229 | Function assay | 20 uM | 1 hr | Inhibition of hypoxia-induced HIF1alpha accumulation in human LN229 cells at 20 uM after 1 hr preincubation measured after 24 hrs by Western blot analysis | 22032632 | |
| U1 | Function assay | 10 uM | 24 hr | Inhibition of NF-kappaB-mediated viral replication in Homo sapiens (human) U1 cells infected with X4 tropic HIV1 NL4-3 at 10 uM after 24 hr by RT-PCR analysis in presence of TNF-alpha | 23290051 | |
| Calu6 | Function assay | 10 uM | 18 hrs | Inhibition of His-tagged Frataxin (unknown origin)/Ubiquitin interaction expressed in human Calu6 cells assessed as increase in frataxin (1-210) precursor level at 10 uM after 18 hrs by Western blotting analysis | 23506486 | |
| HCT116 | Function assay | Inhibition of proteasome in human HCT116 cells assessed as accumulation of p53 by Western blotting analysis | 23547757 | |||
| HCT116 | Apoptosis assay | Induction of apoptosis in human HCT116 cells assessed as induction of PARP cleavage by Western blotting analysis | 23547757 | |||
| HCT116 | Cell cycle assay | 24 hrs | Cell cycle arrest in human HCT116 cells assessed as accumulation at G2/M phase after 24 hrs by propidium iodide staining-based flow cytometric analysis | 23547757 | ||
| HEK293 | Cytotoxicity assay | 0.0001 uM to 100 uM | 48 hrs | Cytotoxicity against human HEK293 cells expressing murine FAP at 0.0001 uM to 100 uM after 48 hrs by CellTiter-Blue assay | 23594271 | |
| A549 | Function assay | 0.025 to 0.5 uM | 24 hrs | Induction of cell death in human A549 cells assessed as accumulation of poly-ubiquitinated proteins at 0.025 to 0.5 uM after 24 hrs by immunoblot assay | 25639862 | |
| A549 | Function assay | 0.025 to 0.5 uM | 24 hrs | Induction of cell death in human A549 cells assessed as stabilization of p53 at 0.025 to 0.5 uM after 24 hrs by immunoblot assay | 25639862 | |
| A549 | Function assay | 0.025 to 0.1 uM | 24 hrs | Induction of cell death in human A549 cells assessed as accumulation of Noxa at 0.025 to 0.1 uM after 24 hrs by immunoblot assay | 25639862 | |
| AMO1 | Antitumor assay | 1 mg/kg | Antitumor activity against human AMO1 cells xenografted in nude SCID beige mouse assessed as tumor growth inhibition at 1 mg/kg, iv administered twice per week | 26565666 | ||
| MCF7 | Function assay | 35 nM | 4 hrs | Inhibition of 26S proteasome in human MCF7 cells assessed as accumulation of high molecular weight polyubiquitin-conjugated proteins at 35 nM after 4 hrs by Western blot analysis | 27994734 | |
| MDA-MB-468 | Function assay | 35 nM | 4 hrs | Inhibition of 26S proteasome in human MDA-MB-468 cells assessed as accumulation of high molecular weight polyubiquitin-conjugated proteins at 35 nM after 4 hrs by Western blot analysis | 27994734 | |
| MDA-MB-231 | Function assay | 1 uM | Inhibition of trypsin like activity of 26S proteasome derived from human MDA-MB-231 cells at 1 uM | 28291344 | ||
| MDA-MB-231 | Function assay | 1 uM | Inhibition of caspase like activity of 26S proteasome derived from human MDA-MB-231 cells at 1 uM | 28291344 | ||
| MDA-MB-231 | Function assay | 1 uM | Inhibition of chymotrypsin like activity of 26S proteasome derived from human MDA-MB-231 cells at 1 uM | 28291344 | ||
| SK-N-SH | Cytotoxicity assay | 0.1 to 1 uM | 24 hrs | Cytotoxicity against human SK-N-SH cells assessed as reduction in cell viability at 0.1 to 1 uM after 24 hrs by MTT assay | 29269255 | |
| MYCN2 | Cytotoxicity assay | 0.1 to 1 uM | 24 hrs | Cytotoxicity against human MYCN2 cells assessed as reduction in cell viability at 0.1 to 1 uM after 24 hrs by MTT assay | 29269255 | |
| U266 | Apoptosis assay | 2.5 nM | 24 hrs | Induction of apoptosis in human U266 cells at 2.5 nM after 24 hrs by Annexin V/propidium iodide staining based flow cytometry | 29304284 | |
| RPMI8226 | Apoptosis assay | 2.5 nM | 24 hrs | Induction of apoptosis in human RPMI8226 cells at 2.5 nM after 24 hrs by Annexin V/propidium iodide staining based flow cytometry | 29304284 | |
| NCI-H929 | Apoptosis assay | 2.5 nM | 24 hrs | Induction of apoptosis in human NCI-H929 cells at 2.5 nM after 24 hrs by Annexin V/propidium iodide staining based flow cytometry | 29304284 | |
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 29435139 | |||
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 29435139 | |||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | |||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | |||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | |||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | |||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | |||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | |||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | |||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | |||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | |||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | |||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells | 29435139 | |||
| fibroblast | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 29435139 | |||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells | 29435139 | |||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells | 29435139 | |||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells | 29435139 | |||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 29435139 | |||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 29435139 | |||
| Rh30 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 29435139 | |||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 29435139 | |||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells | 29435139 | |||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells | 29435139 | |||
| Rh30 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells | 29435139 | |||
| fibroblast | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells | 29435139 | |||
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells | 29435139 | |||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells | 29435139 | |||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells | 29435139 | |||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells | 29435139 | |||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells | 29435139 | |||
| Daoy | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells | 29435139 | |||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells | 29435139 | |||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells | 29435139 | |||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells | 29435139 | |||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | |||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | |||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | |||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | |||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 29435139 | |||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells | 29435139 | |||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 29435139 | |||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells | 29435139 | |||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells | 29435139 | |||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells | 29435139 | |||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells | 29435139 | |||
| HL60 | Function assay | 1 to 100 nM | 24 hrs | Inhibition of proteasome in human HL60 cells assessed as increase in cleaved PARP expression at 1 to 100 nM after 24 hrs by immunoblot assay | 30365892 | |
| SUP-B15 | Function assay | 1 to 100 nM | 24 hrs | Inhibition of proteasome in imatinib-resistant human SUP-B15 cells assessed as increase in cleaved PARP expression at 1 to 100 nM after 24 hrs by immunoblot assay | 30365892 | |
| SEM | Function assay | 1 to 100 nM | 24 hrs | Inhibition of proteasome in human SEM cells assessed as increase in cleaved PARP expression at 1 to 100 nM after 24 hrs by immunoblot assay | 30365892 | |
| SEM | Function assay | 10 nM | 18 hrs | Inhibition of proteasome in human SEM cells assessed as increase in aggresome accumulation at 10 nM after 18 hrs by by FACS analysis | 30365892 | |
| SEM | Function assay | 10 nM | 18 hrs | Inhibition of proteasome in human SEM cells assessed as increase in aggresome accumulation at 10 nM after 18 hrs by fluorescence microscopic method | 30365892 | |
| HepG2 | Cell viability assay | HepG2 cells viability qHTS for Zika virus inhibitors | 33229545 | |||
| Klicken Sie hier, um weitere experimentelle Daten zu Zelllinien anzuzeigen | ||||||
| Molekulargewicht | 384.24 | Formel | C19H25BN4O4 |
Lagerung (Ab dem Eingangsdatum) | 3 years-20°C (in the dark)powder |
|---|---|---|---|---|---|
| CAS-Nr. | 179324-69-7 | SDF herunterladen | Lagerung von Stammlösungen |
|
|
| Synonyme | LDP-341, MLM341, NSC 681239,PS-341, BTZ | Smiles | B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O | ||
|
In vitro |
DMSO
: 77 mg/mL
(200.39 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Schritt 1: Geben Sie die untenstehenden Informationen ein (Empfohlen: Ein zusätzliches Tier zur Berücksichtigung von Verlusten während des Experiments)
Schritt 2: Geben Sie die In-vivo-Formulierung ein (Dies ist nur der Rechner, keine Formulierung. Bitte kontaktieren Sie uns zuerst, wenn es im Abschnitt "Löslichkeit" keine In-vivo-Formulierung gibt.)
Berechnungsergebnisse:
Arbeitskonzentration: mg/ml;
Methode zur Herstellung der DMSO-Stammlösung: mg Wirkstoff vorgelöst in μL DMSO ( Konzentration der Stammlösung mg/mL, Bitte kontaktieren Sie uns zuerst, wenn die Konzentration die DMSO-Löslichkeit der Wirkstoffcharge überschreitet. )
Methode zur Herstellung der In-vivo-Formulierung: Nehmen Sie μL DMSO Stammlösung, dann hinzufügenμL PEG300, mischen und klären, dann hinzufügenμL Tween 80, mischen und klären, dann hinzufügen μL ddH2O, mischen und klären.
Methode zur Herstellung der In-vivo-Formulierung: Nehmen Sie μL DMSO Stammlösung, dann hinzufügen μL Maisöl, mischen und klären.
Hinweis: 1. Bitte stellen Sie sicher, dass die Flüssigkeit klar ist, bevor Sie das nächste Lösungsmittel hinzufügen.
2. Achten Sie darauf, das/die Lösungsmittel der Reihe nach hinzuzufügen. Sie müssen sicherstellen, dass die bei der vorherigen Zugabe erhaltene Lösung eine klare Lösung ist, bevor Sie mit der Zugabe des nächsten Lösungsmittels fortfahren. Physikalische Methoden wie Vortex, Ultraschall oder ein heißes Wasserbad können zur Unterstützung des Lösens verwendet werden.
| Targets/IC50/Ki |
NF-κB
20S proteasome
(Cell-free assay) 0.6 nM(Ki)
|
|---|---|
| In vitro |
Bortezomib, ein Boronsäure-Dipeptid, ist ein hochselektiver, reversibler Inhibitor des 26S Proteasome, das hauptsächlich beim Abbau fehlgefalteter Proteine fungiert und für die Regulation des Zellzyklus unerlässlich ist. Die Exposition gegenüber dieser Verbindung hat gezeigt, dass sie p21, p27 und p53 sowie die proapoptotischen Bid- und Bax-Proteine, Caveolin-1 und Inhibitor κB-α stabilisiert, was die Aktivierung von NF-κB-induzierten Zellüberlebenswegen verhindert. Es fördert auch die Aktivierung der proapoptotischen c-Jun-NH2-terminalen Kinase sowie der Reaktion auf endoplasmatischen Retikulumstress. Die Veränderung der Spiegel dieser zellulären Proteine führt zur Hemmung der Proliferation, Migration und Förderung der Apoptose von Krebszellen. Es wird gezeigt, dass diese Chemikalie in Zellen eindringt und die Proteasome-vermittelte intrazelluläre Proteolyse langlebiger Proteine mit einer Konzentration hemmt, die 50% der Proteolyse von ~0,1 μM hemmt. Der durchschnittliche Wert für die 50%-ige Wachstumshemmung dieser Verbindung über das gesamte Panel von 60 Krebszelllinien, die aus mehreren menschlichen Tumoren des US National Cancer Institute (NCI) stammen, beträgt 7 nM. Die Behandlung von PC-3-Zellen damit (100 nM) für 8 Stunden führt zu einer Akkumulation von Zellen in G2-M, mit einer entsprechenden Abnahme der Zellzahl in G1. Es tötet PC-3-Zellen bei 24 und 48 Stunden mit IC50 von 100 bzw. 20 nM ab. Dieses Mittel induziert Kernkondensation 16–24 Stunden nach der Behandlung. Seine Behandlung führt zu PARP-Spaltung in einer zeitabhängigen Weise, wobei Konzentrationen von nur 100 nM nach 24 Stunden wirksam sind. |
| Kinase-Assay |
Kinetische Methoden
|
|
Bei einem typischen kinetischen Lauf werden 2,00 mL Assaypuffer (20 mM HEPES, 0,5 mM EDTA, 0,035% SDS, pH 7,8) und Suc-Leu-Leu-Val-Tyr-AMC in DMSO in eine 3 mL Fluoreszenzküvette gegeben, und die Küvette wird in den ummantelten Zellenhalter eines Fluoreszenzspektrophotometers gestellt. Die Reaktionstemperatur wird durch ein zirkulierendes Wasserbad bei 37℃ gehalten. Nachdem die Reaktionslösung das thermische Gleichgewicht erreicht hat (5 Minuten), werden 1 μL–10 μL der Stammenzymlösung zur Küvette gegeben. Der Reaktionsfortschritt wird durch die Zunahme der Fluoreszenzemission bei 440 nm (λex= 380 nm) überwacht, die mit der Abspaltung von AMC von Peptid-AMC-Substraten einhergeht.
|
|
| In vivo |
Die Antikrebswirkungen von Bortezomib als Einzelwirkstoff wurden in Xenograft-Modellen von multiplem Myelom, adulter T-Zell-Leukämie, Lungen-, Brust-, Prostata-, Bauchspeicheldrüsen-, Kopf- und Hals- sowie Darmkrebs und bei Melanomen nachgewiesen. Die orale Verabreichung dieser Verbindung in einer Dosis von 1,0 mg/kg täglich über 18 Tage führt zu einer Verzögerung des Tumorwachstums sowie zu einer Abnahme der Anzahl von Metastasen im Lewis-Lungenkrebsmodell. Diese Verbindung in einer Einzeldosis von bis zu 5 mg/kg verringerte signifikant den überlebenden Anteil von Brusttumorzellen. Die wöchentliche Verabreichung dieser Chemikalie in einer Dosis von 1,0 mg/kg über 4 Wochen reduziert das Tumorwachstum um 60% in murinen Xenograft-Modellen von Prostatakrebs. Die Behandlung mit diesem Mittel in einer Dosis von 1,0 mg/kg über 4 Wochen führt zu einer 72%igen oder 84%igen Reduktion des Wachstums von Bauchspeicheldrüsenkrebs-Xenografts bei Mäusen sowie zu einer Zunahme der Tumorzellapoptose. Diese Verbindung in einer Dosis von 1,0 mg/kg führt zu einer signifikanten Hemmung des Wachstums menschlicher Plasmozytom-Xenografts, einer Zunahme der Tumorzellapoptose und des Gesamtüberlebens sowie einer Abnahme der Tumorangiogenese. |
Literatur |
|
| Methoden | Biomarker | Bilder | PMID |
|---|---|---|---|
| Western blot | phospho-PERK / ATF-4 GRP-78 / GADD-34 pro-caspase-12 / pro-caspase-3 pro-caspase-9 p-IκBα / IκBα COX-2 / cIAP2 |
|
15509775 |
| Immunofluorescence | Vimentin Ubiquitin |
|
19010849 |
| Growth inhibition assay | Cell viability |
|
20571067 |
| ELISA | IL-8 |
|
24085292 |
(Daten von https://clinicaltrials.gov, aktualisiert am 2024-05-22)
| NCT-Nummer | Rekrutierung | Erkrankungen | Sponsor/Kooperationspartner | Startdatum | Phasen |
|---|---|---|---|---|---|
| NCT05599880 | Recruiting | Relapsed/Refractory Immune Thrombocytopenia |
Seoul National University Hospital |
July 7 2023 | Phase 2 |
| NCT05781425 | Recruiting | Chemotherapy-induced Peripheral Neuropathy |
Odense University Hospital|Aarhus University Hospital|Sygehus Lillebaelt|University of Southern Denmark |
May 12 2023 | -- |
| NCT05383547 | Unknown status | Bortezomib|Glomerulonephritis|MN|MPGN|FSGS|IgA Nephropathy |
Ruijin Hospital |
August 2 2022 | Not Applicable |
| NCT04915248 | Recruiting | Plasmablastic Lymphoma |
Fondazione Italiana Linfomi - ETS|Janssen-Cilag S.p.A. |
July 11 2022 | Phase 2 |
| NCT04656951 | Recruiting | Multiple Myeloma |
University of Cologne|Janssen-Cilag G.m.b.H |
June 1 2021 | Phase 2 |
Tel: +1-832-582-8158 Ext:3
Wenn Sie weitere Fragen haben, hinterlassen Sie bitte eine Nachricht.
Frage 1:
On your website, it is mentioned that it should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?
Antwort:
S1013 This compound in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve it in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.